Keyphrases
5-fluorouracil (5-FU)
8%
Adult T-cell Leukemia
37%
Advanced Solid Tumors
13%
Adverse Events
8%
AIDS/HIV
19%
Amino Acids
9%
Androgen Receptor
12%
Antiretroviral Therapy
8%
Apoptosis
10%
Bone Loss
8%
Bone Marrow
10%
Bone Metastasis
15%
Breast Cancer
32%
Breast Cancer Patients
16%
C-C Chemokine Receptor Type 5 (CCR5)
8%
C-X-C Chemokine Receptor Type 4 (CXCR4)
8%
Cancer Patients
10%
Cancer Treatment
7%
Chemotherapy
33%
Clinical Outcomes
8%
Clinical Trials
14%
Co-receptor
9%
Confidence Interval
11%
Docetaxel
8%
Dose Escalation
9%
Dose-limiting Toxicity
8%
Envelope Protein
10%
ErbB2
8%
Estrogen Receptor 1 (ESR1)
11%
Gemcitabine
17%
Gene Expression
14%
Gp120
8%
Heat Shock Protein 90 (Hsp90)
9%
HIV-2
8%
Human Epidermal Growth Factor Receptor 2 (HER2)
26%
Human Immunodeficiency Virus Type 1 (HIV-1)
82%
Human Immunodeficiency Virus Type 2
8%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
100%
Immortalization
8%
In Cancer
16%
Infected Cells
10%
Infectivity
10%
Integrin
18%
Interferon-α (IFN-α)
15%
Liposomal Irinotecan
8%
Lymphoma
11%
Macrophages
16%
Malignancy
17%
Mass Spectrometry
8%
Melanoma
12%
Metastasis
10%
Metastatic Breast Cancer
17%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
11%
Metastatic Disease
7%
Metastatic Pancreatic Cancer
14%
Metastatic Pancreatic Ductal Adenocarcinoma
14%
Microphthalmia-associated Transcription Factor
9%
Monotherapy
8%
Mouse Model
15%
Neoadjuvant
8%
Neratinib
12%
NF-B
15%
Oncogene
15%
Oncoprotein
8%
Osteoclast
13%
Overall Survival
22%
Overexpression
8%
Paclitaxel
7%
Pancreatic Adenocarcinoma
8%
Pancreatic Cancer
33%
Pancreatic Ductal Adenocarcinoma
25%
Partial Response
8%
Patient-derived Xenograft
24%
Phase II Trial
12%
Phosphorylation
24%
Poor Prognosis
10%
Progression-free Survival
11%
Prostate Cancer
16%
Randomized Phase II Trial
9%
Retrovirus
12%
Solid Tumors
9%
T Cell Lines
8%
T Cells
39%
Targeted Therapy
11%
Transgenic Mice
9%
Trastuzumab
19%
Triple-negative Breast Cancer
21%
Tropics
8%
Tumor
67%
Tumor Cells
16%
Tumor Growth
24%
Tumor Microenvironment
13%
Tumorigenesis
18%
Upstream Open Reading Frame (uORF)
11%
V3 Loop
11%
Viral
9%
Virus
30%
Virus Replication
8%
Virus Type
9%
Zoledronic Acid
9%
Medicine and Dentistry
Abdominal Cancer
5%
Adult T-Cell Leukemia/Lymphoma
27%
Adverse Event
10%
Androgen Receptor
8%
Arm
14%
Biological Marker
10%
Bone Cancer
7%
Bone Metastasis
15%
Breast Cancer
49%
Cancer
28%
Cancer Cell
7%
Cancer Therapy
7%
Carcinogenesis
9%
Castration Resistant Prostate Cancer
9%
Cell Line
6%
Chemoradiotherapy
5%
Clear Cell Renal Cell Carcinoma
6%
Clinical Trial
21%
Diseases
31%
Drive
5%
Epidermal Growth Factor Receptor
5%
Epidermal Growth Factor Receptor 2
5%
Fluorouracil
5%
Gamma Urogastrone
5%
Gemcitabine
10%
Gene Expression
5%
Hodgkin's Lymphoma
5%
Hormone Therapy
10%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
6%
Human Immunodeficiency Virus
20%
Human Immunodeficiency Virus 1
7%
Human T Cell Leukemia Virus
8%
Human T-Lymphotropic Virus 1
29%
Immunotherapy
13%
In Vitro
8%
Infection
6%
Integrin
12%
Interferon
6%
Leukemia
6%
Lymphocyte
6%
Macrophage
7%
Magnetic Resonance Imaging
5%
Malignant Neoplasm
28%
Melanoma
13%
Metastatic Breast Cancer
11%
Metastatic Carcinoma
24%
Microphthalmia Associated Transcription Factor
8%
Multiple Myeloma
8%
Neoadjuvant Chemotherapy
6%
Neoplasm
80%
Neratinib
6%
Nivolumab
5%
Non-Hodgkin Lymphoma
6%
Oncology
7%
Oncoprotein
5%
Osteoclast
10%
Osteolysis
10%
Overall Survival
22%
Paclitaxel
6%
Pancreas Adenocarcinoma
32%
Pancreas Cancer
35%
Phase II Trials
7%
Positron Emission Tomography
8%
Programmed Cell Death
9%
Progression Free Survival
12%
Prostate Cancer
20%
Proteomics
5%
Radiation Therapy
11%
Recurrent Disease
7%
Solid Malignant Neoplasm
7%
Stem Cell
5%
Surgery
7%
T Cell
22%
T Lymphocyte Receptor
5%
Targeted Therapy
13%
Transgenic Mouse
9%
Trastuzumab
14%
Triple Negative Breast Cancer
11%
Tumor Cell
10%
Tumor Microenvironment
6%
Tumor Progression
24%
Tumor Xenograft
6%
Virus
5%
Xenograft
17%
Zoledronic Acid
7%